BLA 761208 · Seagen
Tivdak
Tisotumab Vedotin-Tftv · Injection
NovelAccelerated approvalPriority reviewCDER novel approval, Sep 20, 2021: To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Last checked: Nov 20, 2026Latest source record: Nov 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Sep 20, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
13
2 Phase 3, 1 recruiting
FAERS reports
971
609 serious, 81 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: OCULAR TOXICITY • TIVDAK can cause severe ocular toxicities resulting in changes in vision, including severe vision loss, and corneal ulceration. [see Warnings and Precautions (5.1) ]. • Conduct an ophthalmic exam, including an assessment of ocular symptoms, visual acuity, and slit lamp exam of the anterior segment of the eye prior to initiation of TIVDAK, prior to every cycle for the first nine cycles, and as clinically indicated. [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . • Adhere to the required premedication and eye care before, during, and after infusion. [see Dosage and Administration (2.2) ]. • Withhold TIVDAK until improvement and resume, reduce the dose, or permanently discontinue, based on severity [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) ]. WARNING: OCULAR TOXICITY See full prescribing information for...
What it is approved for
From the label in effect Oct 16, 2026.
TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. ( 1 )
Mechanism: Tisotumab vedotin-tftv is a tissue factor (TF)-directed antibody drug conjugate (ADC). The antibody is a human IgG1 directed against cell surface TF. TF is the primary initiator of the extrinsic blood coagulation cascade. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Nonclinical data suggests that the anticancer activity of tisotumab vedotin-tftv is due to the binding of the ADC to TF expressing cancer cells, followed by internalization of the ADC-TF complex, and release of MMAE via proteolytic cleavage. MMAE disrupts...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 29, 2024 Supplement 7 · Efficacy · priority review LabelLetter
- Sep 20, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelLetterReview
1 products under this application
- TIVDAK · TISOTUMAB VEDOTIN-TFTV 40MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tisotumab Vedotin" as an intervention, any sponsor and status, largest first.
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06459180 · 686 participants (planned) · Start Jul 24, 2024 · Primary completion Jun 15, 2028
Drug: Sacituzumab Tirumotecan; Pemetrexed and 5 more · For: Cervical Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 240 sites in all
- Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerPivotal-lookingCompleted
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT04697628 · 502 participants · Start Feb 22, 2021 · Primary completion Jul 24, 2023
Drug: tisotumab vedotin; topotecan and 4 more · For: Cervical Cancer
Sites: Glendale, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 211 sites in all
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruiting
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT03485209 · 350 participants · Start Jun 25, 2018 · Primary completion Mar 20, 2026
Drug: tisotumab vedotin; pembrolizumab and 2 more · For: Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer and 1 more
Sites: Encinitas, California; La Jolla, California; Sacramento, California · 175 sites in all
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT03786081 · 214 participants · Start Feb 27, 2019 · Primary completion Mar 19, 2026
Drug: Tisotumab Vedotin; Bevacizumab and 2 more · For: Cervical Cancer
Sites: Phoenix, Arizona; Orange, California; Sylmar, California · 71 sites in all
Seagen Inc.Pfizer (PFE)
NCT02001623 · 195 participants · Start Nov 30, 2013 · Primary completion May 2, 2019
Drug: Tisotumab Vedotin (HuMax-TF-ADC) · For: Ovary Cancer; Cervix Cancer; Endometrium Cancer and 5 more
Sites: Orange, California; New Haven, Connecticut; Miami, Florida · 29 sites in all
Seagen Inc.Pfizer (PFE)
NCT03438396 · 102 participants · Start Jun 12, 2018 · Primary completion Feb 6, 2020
Drug: tisotumab vedotin · For: Cervical Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 53 sites in all
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruiting
PfizerPfizer (PFE)
NCT06952660 · 100 participants (planned) · Start May 7, 2025 · Primary completion Dec 13, 2028
Drug: TIVDAK · For: Cervical Cancer
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tempe, Arizona · 135 sites in all
Seagen Inc.Pfizer (PFE)
NCT03657043 · 98 participants · Start Mar 20, 2019 · Primary completion Feb 8, 2022
Drug: tisotumab vedotin · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Sites: San Jose, California; Fort Collins, Colorado; Miami, Florida · 37 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression80
- neuropathy peripheral79
- nausea66
- dry eye55
- conjunctivitis52
- rash47
- off label use42
- death40
- diarrhoea40
- anaemia35
- fatigue34
- eye disorder31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 6 |
| 2020 | 14 |
| 2021 | 24 |
| 2022 | 172 |
| 2023 | 186 |
| 2024 | 182 |
| 2025 | 232 |
| 2026 | 155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tivdak (Tisotumab Vedotin-Tftv)
2024 spending
$1.1M
Beneficiaries
n/a
45 claims
Per beneficiary
n/a
$6,724.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $400,835 |
| 2023 | $703,742 |
| 2024 | $1,129,746 |
Part B: Tivdak (TIsotumab Vedotin-Tftv) · HCPCS J9273
2024 spending
$16.2M
Beneficiaries
189
765 claims
Per beneficiary
$85,824
2024 ASP limit $174.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $6,726,328 |
| 2023 | $11,221,550 |
| 2024 | $16,220,713 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Vergote I, González-Martín A, Fujiwara K, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL, Lorusso D, Gennigens C, et al. · Lancet Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
- Safety and efficacy of tisotumab vedotin with cervical cancers: A systematic review and meta-analysis.
Mokresh ME, Alomari O, Varda A, et al. · J Obstet Gynaecol Res 2024 · Systematic Review, Meta-Analysis
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS, Concin N, Hong DS, et al. · Lancet Oncol 2019 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE, et al. · J Clin Oncol 2023 · Multicenter Study, Clinical Trial, Phase I
- Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Yonemori K, Kuboki Y, Hasegawa K, et al. · Cancer Sci 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.